Sugi Predict

Sugi Predict / Targets / PIK3R2

PIK3R2

Phosphatidylinositol 3-kinase regulatory subunit beta · O00459 · PIK3R2 on Sugi Atlas →

29,594 patent compounds predicted against PIK3R2, 19,580 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL7050 SCHEMBL7050 1.00 20/20
SCHEMBL7052 SCHEMBL7052 1.00 20/20
SCHEMBL7070 SCHEMBL7070 1.00 20/20
SCHEMBL7166 SCHEMBL7166 1.00 20/20
SCHEMBL7186 SCHEMBL7186 1.00 20/20
SCHEMBL7257 SCHEMBL7257 1.00 20/20
SCHEMBL7283 SCHEMBL7283 1.00 20/20
SCHEMBL7291 SCHEMBL7291 1.00 20/20
SCHEMBL7499 SCHEMBL7499 1.00 20/20
SCHEMBL7530 SCHEMBL7530 1.00 20/20
SCHEMBL7558 SCHEMBL7558 1.00 20/20
SCHEMBL7575 SCHEMBL7575 1.00 20/20
SCHEMBL7603 SCHEMBL7603 1.00 20/20
SCHEMBL7607 SCHEMBL7607 1.00 20/20
SCHEMBL7619 SCHEMBL7619 1.00 20/20
SCHEMBL7633 SCHEMBL7633 1.00 20/20
SCHEMBL7659 SCHEMBL7659 1.00 20/20
SCHEMBL7693 SCHEMBL7693 1.00 20/20
SCHEMBL7700 SCHEMBL7700 1.00 20/20
SCHEMBL7728 SCHEMBL7728 1.00 20/20

Clinical trials — most relevant to PIK3R2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway PHASE4COMPLETED
Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations PHASE3COMPLETED
Adjuvant Low Dose Aspirin in Colorectal Cancer PHASE3ACTIVE_NOT_RECRUITING
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder PHASE2/PHASE3RECRUITING
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid PHASE2COMPLETED
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) PHASE2ACTIVE_NOT_RECRUITING
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome PHASE1/PHASE2COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss PHASE2RECRUITING
A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia PHASE2WITHDRAWN
STAR Cape+BKM120 MBC With Brain Met PHASE2COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer PHASE1/PHASE2RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery PHASE1COMPLETED
Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid Tumors PHASE1COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers PHASE1COMPLETED
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
Partial PTEN Deletion in Breast Cancer nanUNKNOWN
PIK3CA in HER2+ BC and pCR Trial nanUNKNOWN
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors nanUNKNOWN
PI3K Pathway Activation Markers in ER-Positive, HER2-Negative Breast Cancer: A Clinicopathologic Study nanNOT_YET_RECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis nanUNKNOWN
Exploring the Link Between Cancer Genetics and PPSP nanUNKNOWN
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PIK3R2 binder may also engage these)

ProteinNameSimilarity
P23726 — 1.000 P23726 →
O08908 — 0.998 O08908 →
Q63788 — 0.997 Q63788 →
PKN1 Serine/threonine-protein kinase N1 0.969 landscape →
Q9Z0G0 — 0.965 Q9Z0G0 →
A1A4I4 — 0.965 A1A4I4 →
O14908 — 0.963 O14908 →
O95294 — 0.962 O95294 →
P70268 — 0.962 P70268 →
Q5RE34 — 0.960 Q5RE34 →
O43374 — 0.960 O43374 →
Q29RM4 — 0.960 Q29RM4 →
Q5ZIW1 — 0.960 Q5ZIW1 →
Q9Z268 — 0.959 Q9Z268 →
A4K436 — 0.958 A4K436 →
C9J798 — 0.958 C9J798 →
Q63433 — 0.958 Q63433 →
Q9HCE6 — 0.957 Q9HCE6 →
D3ZVM4 — 0.957 D3ZVM4 →
Q5XIS9 — 0.957 Q5XIS9 →
Q08DP6 — 0.957 Q08DP6 →
A2AWP8 — 0.956 A2AWP8 →
Q9NRU3 — 0.956 Q9NRU3 →
Q9Z254 — 0.956 Q9Z254 →
O62683 — 0.955 O62683 →
Q5R5M3 — 0.955 Q5R5M3 →
Q9NZ71 — 0.955 Q9NZ71 →
Q8TBN0 — 0.955 Q8TBN0 →
Q66T02 — 0.955 Q66T02 →
Q8BZ03 — 0.955 Q8BZ03 →